Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Oncology
Anastasia Alataki, Mitch Dowsett
Summary: Endocrine therapies are the main treatment for hormone-dependent breast cancer, but HER2 signaling contributes to resistance and affects treatment efficacy. HER2 overexpression plays a role in resistance to endocrine therapies in breast cancer patients, impacting their clinical outcomes.
ENDOCRINE-RELATED CANCER
(2022)
Article
Cell & Tissue Engineering
Jiachen Sun, Hongqing Zhao, Chuan'an Shen, Shiyi Li, Wen Zhang, Jinglong Ma, Zhisheng Li, Ming Zhang, Jianqiu Yang
Summary: Aging affects the function of epidermal stem cells (EpiSCs) and wound healing by reducing the activity of the PI3K/Akt pathway. Tideglusib can promote the proliferation, migration, and wound healing of EpiSCs by activating the PI3K/Akt pathway.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Developmental Biology
Jung-Chien Cheng, Yibo Gao, Jiaye Chen, Qingxue Meng, Lanlan Fang
Summary: This study reveals that EGF-induced downregulation of CTGF mediates the EGF-stimulated human trophoblast cell invasion. It provides important insights into the molecular mechanisms mediating EGF-stimulated human trophoblast cell invasion and increases the understanding of the biological functions of CTGF in the human placenta.
Article
Immunology
Zhengguang Zhang, Yuanyuan Guo, Meijuan Chen, Feiyan Chen, Bing Liu, Cunsi Shen
Summary: The combination of kaempferol (KAE) and erlotinib (ERL) significantly inhibited cell proliferation and promoted apoptosis in pancreatic cancer cells, potentially through inhibiting the PI3K/AKT signaling pathway and EGFR TKI resistance. Patients with high EGFR expression in pancreatic cancer had a lower survival rate.
INFLAMMOPHARMACOLOGY
(2021)
Article
Oncology
Ivica Ratosa, Nika Dobnikar, Michele Bottosso, Maria Vittoria Dieci, William Jacot, Stephane Pouderoux, Domen Ribnikar, Lea Sinoquet, Valentina Guarneri, Tanja Znidaric, Amelie Darlix, Gaia Griguolo
Summary: Leptomeningeal metastases (LM) in patients with HER2+ breast cancer are rare but often fatal. This multicentric study retrospectively gathered data from 82 patients with advanced HER2+ breast cancer and LM. The study found that absence of neurological symptoms and receiving radiotherapy were associated with prolonged overall survival.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F. Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The US FDA approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy specifically for HER2-low metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Yinjie Niu, Xiaozhe Fu, Qiang Lin, Hongru Liang, Xia Luo, Shaozhi Zuo, Lihui Liu, Ningqiu Li
Summary: Infectious spleen and kidney necrosis virus disease (ISKNVD) caused significant economic losses to the fishery industry. The activation of EGFR and PI3K-Akt played crucial roles in ISKNV invasion. This study revealed that ISKNV infection rapidly induced activation of EGFR and subsequently activated the downstream signalling pathway PI3K-Akt, which facilitated ISKNV entry into host cells. This research provides a better understanding of the molecular regulatory mechanisms involved in ISKNV invasion through the EGFR-PI3K-Akt pathway.
JOURNAL OF GENERAL VIROLOGY
(2023)
Review
Oncology
Volkmar Mueller, Rupert Bartsch, Nancy U. Lin, Filippo Montemurro, Mark D. Pegram, Sara M. Tolaney
Summary: This systematic literature review provides a comprehensive overview of the epidemiology, unmet needs, and treatment landscape for patients with HER2+ metastatic breast cancer and brain metastases. There is a need for standardization of clinical trial design to ensure all types of brain metastases can access effective treatments.
CANCER TREATMENT REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Xiao-Shun He, Wen-Long Ye, Yu-Juan Zhang, Xiao-Qin Yang, Feng Liu, Jing-Ru Wang, Xiao-Lu Ding, Yun Yang, Ruo-Nan Zhang, Yuan-Yuan Zhao, Hai-Xia Bi, Ling-Chuan Guo, Wen-Juan Gan, Hua Wu
Summary: In this study, we found that BEST4 promotes cell proliferation and metastasis in colorectal cancer. It activates the Akt signaling pathway by binding to the regulatory subunit p85 alpha of PI3K, leading to the expression of critical regulators such as MYC and CCND1. Additionally, high expression of BEST4 is associated with poor prognosis in patients.
Article
Chemistry, Analytical
Minghao Qiu, Yuqing Ren, Lumin Huang, Xueying Zhu, Tikai Liang, Meijin Li, Dianping Tang
Summary: A sensitive electrochemical immunoassay platform for quantitatively monitoring human epidermal growth factor receptor 2 (HER2) is developed using iron nitrogen-doped carbon (FeNC) nanozyme-modified screen-printed carbon electrode and chronoamperometry. The system demonstrates good amperometric response and can detect target HER2 as low as 4.5 pg/mL. FeNC nanozyme-based sensing strategy offers high specificity and long-term stability, providing a new opportunity for protein diagnostics.
Article
Medicine, General & Internal
Guochun Zhang, Chongyang Ren, Cheukfai Li, Yulei Wang, Bo Chen, Lingzhu Wen, Minghan Jia, Kai Li, Hsiaopei Mok, Li Cao, Xiaoqing Chen, Jiali Lin, Guangnan Wei, Yingzhi Li, Yuchen Zhang, Charles M. Balch, Ning Liao
Summary: This study analyzed the clinical and genomic data of 523 Chinese women with breast cancer and found that HER2-low breast tumors have distinct clinical and molecular features compared to HER2-zero tumors. The study also showed differences in treatment response and relapse rates between HER2-low and HER2-zero tumors.
Review
Oncology
Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan, Xiaoming Xie
Summary: This article provides an overview of the therapeutic landscape of HER2+BC by reviewing research results and introducing the latest evidence, aiming to provide a reference for clinical treatment.
Review
Oncology
Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Summary: HR+/HER2+ metastatic breast cancer is a unique subtype of breast cancer. Combination regimens and endocrine therapy can provide long-term disease control, but accurately identifying the subset of patients who can benefit from de-chemotherapy treatment strategy is challenging.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Akiyoshi Kasuga, Takashi Semba, Ryo Sato, Hiroyuki Nobusue, Eiji Sugihara, Hiromasa Takaishi, Takanori Kanai, Hideyuki Saya, Yoshimi Arima
Summary: Biliary tract cancer (BTC) arises from biliary epithelial cells (BECs) in intrahepatic cholangiocarcinoma (IHCC), gallbladder cancer (GC), and extrahepatic cholangiocarcinoma (EHCC). The manipulation of EpCAM-positive BECs in organoid culture has been shown to be crucial for maintaining the characteristics, stemness, and tumorigenic activity of BTC-initiating cells. The syngeneic mouse models recapitulate the pathological features of human IHCC, GC, and EHCC, and could serve as valuable tools for investigating BTC carcinogenesis and developing new therapeutic strategies.
Article
Orthopedics
Takatsune Shimizu, Kiyomi Kimura, Eiji Sugihara, Sayaka Yamaguchi-Iwai, Hiroyuki Nobusue, Oltea Sampetrean, Yuji Otsuki, Yumi Fukuchi, Kaori Saitoh, Keiko Kato, Tomoyoshi Soga, Akihiro Muto, Hideyuki Saya
Summary: Trametinib shows better anti-tumor effects in nonadherent AXT cells and U2OS cells in osteosarcoma. The interaction between MAPK/ERK and PI3K/AKT signaling pathways in osteosarcoma affects cell survival and therapeutic outcomes, which are dependent on cellular context.
JOURNAL OF ORTHOPAEDIC RESEARCH
(2021)
Article
Virology
Masaru Takeshita, Naoshi Nishina, Saya Moriyama, Yoshimasa Takahashi, Yoshifumi Uwamino, Mika Nagata, Wataru Aoki, Katsunori Masaki, Makoto Ishii, Hideyuki Saya, Yasushi Kondo, Yuko Kaneko, Katsuya Suzuki, Koichi Fukunaga, Tsutomu Takeuchi
Summary: The study found that asymptomatic and mild COVID-19 patients had inadequate humoral immune responses, with most antibodies being correlated with disease severity, symptoms such as pneumonia, lymphopenia, and certain serological markers, and some patients failing to develop antibodies against the virus.
Article
Oncology
Yoichi Fujii, Yusuke Sato, Hiromichi Suzuki, Nobuyuki Kakiuchi, Tetsuichi Yoshizato, Andrew T. Lenis, Shigekatsu Maekawa, Akira Yokoyama, Yasuhide Takeuchi, Yoshikage Inoue, Yotaro Ochi, Yusuke Shiozawa, Kosuke Aoki, Kenichi Yoshida, Keisuke Kataoka, Masahiro M. Nakagawa, Yasuhito Nannya, Hideki Makishima, Jimpei Miyakawa, Taketo Kawai, Teppei Morikawa, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Genta Nagae, Masashi Sanada, Eiji Sugihara, Taka-Aki Sato, Tohru Nakagawa, Masashi Fukayama, Tetsuo Ushiku, Hiroyuki Aburatani, Satoru Miyano, Jonathan A. Coleman, Yukio Homma, David B. Solit, Haruki Kume, Seishi Ogawa
Summary: Through an integrated genetic study involving 199 UTUC samples, the landscape of genetic alterations in UTUC was delineated, enabling genetic/molecular classification. UTUC is classified into five subtypes based on the mutational status of TP53, MDM2, RAS, and FGFR3, with discrete profiles of gene expression, tumor location/histology, and clinical outcome. Sequencing of urine sediment-derived DNA has high diagnostic value for UTUC with 82.2% sensitivity and 100% specificity, providing a solid basis for better diagnosis and management of UTUC.
Article
Genetics & Heredity
Tasuku Mariya, Takema Kato, Takeshi Sugimoto, Syunsuke Miyai, Hidehito Inagaki, Tamae Ohye, Eiji Sugihara, Yukako Muramatsu, Seiji Mizuno, Hiroki Kurahashi
Summary: By using adaptive sampling and nanopore long-read sequencing technology, we successfully determined the structures of two sSMCs with complex rearrangements. Adaptive sampling enables rapid enrichment of target regions and improves sequencing coverage, thus facilitating the analysis of complex chromosomal rearrangements.
JOURNAL OF HUMAN GENETICS
(2022)
Article
Cell & Tissue Engineering
Shiho Aizawa, Ken Nishimura, Gonzalo Seminario Mondejar, Arun Kumar, Phuong Linh Bui, Yen Thi Hai Tran, Akihiro Kuno, Masafumi Muratani, Shin Kobayashi, Tsukasa Nabekura, Akira Shibuya, Eiji Sugihara, Taka-Aki Sato, Aya Fukuda, Yohei Hayashi, Koji Hisatake
Summary: A recent study has found that the initial phase of X chromosome reactivation (XCR) occurs at clustered genes during the reprogramming of murine female somatic cells, and histone demethylation may play a role in this process.
Article
Cell & Tissue Engineering
Le Phuong Hoang Anh, Ken Nishimura, Akihiro Kuno, Nguyen Thuy Linh, Tetsuo Kato, Manami Ohtaka, Mahito Nakanishi, Eiji Sugihara, Taka-Aki Sato, Yohei Hayashi, Aya Fukuda, Koji Hisatake
Summary: Somatic cell reprogramming proceeds through a series of events to generate induced pluripotent stem cells (iPSCs). In this study, the researchers found that the downregulation of Osr2 is crucial for efficient reprogramming by using a cell-based model. Osr2 acts as a novel EMT regulator and its downregulation diminishes TGF-beta signaling and activates Wnt signaling, promoting MET and acquiring pluripotency.
Article
Oncology
Ritsuko Harigai, Ryo Sato, Chikako Hirose, Toshiki Takenouchi, Kenjiro Kosaki, Takanori Hirose, Hideyuki Saya, Yoshimi Arima
Summary: Germline mutations of NF1 can cause neurofibromatosis type 1 and lead to the development of malignant tumors. By sequencing the genomic DNA of NF1-derived tumors, additional genetic alterations associated with tumor malignancy were identified. The study suggests that a combination of NF1 and PTPN11 mutations drives the malignancy of NF1 cells, and the suppression of SHP-2 by BRAP may be a potential therapeutic strategy for NF1-associated malignant tumors.
Article
Biology
Sayaka Ueno, Tamotsu Sudo, Hideyuki Saya, Eiji Sugihara
Summary: This study reveals that pigment epithelium-derived factor (PEDF) promotes the dissemination of ovarian cancer by inducing IL-10 expression in macrophages. High PEDF gene expression is associated with poor prognosis in ovarian cancer patients, and elevated PEDF levels are correlated with early recurrence. BET inhibitors reduce PEDF expression and limit both cancer cell survival and macrophage induction.
COMMUNICATIONS BIOLOGY
(2022)
Article
Cell Biology
Takatsune Shimizu, Eiji Sugihara, Hideyuki Takeshima, Hiroyuki Nobusue, Rui Yamaguchi, Sayaka Yamaguchi-Iwai, Yumi Fukuchi, Toshikazu Ushijima, Akihiro Muto, Hideyuki Saya
Summary: Mutant p53 in osteosarcoma cells does not suppress the activity of wild-type p53. Targeting mutant p53 R270C (equivalent to human R273C) has limited therapeutic potential, as it does not prevent invasion and metastasis in cells.
Article
Biochemistry & Molecular Biology
Haruki Inoue, Eriko Aimono, Akiyoshi Kasuga, Haruto Tanaka, Aika Iwasaki, Hideyuki Saya, Yoshimi Arima
Summary: Our mouse BTC models are suitable for studying BTC carcinogenesis and may contribute to the development of new therapeutic strategies. Analysis of images of mouse and human tumor tissues reveals similarities in tissue structure between the two, suggesting similarities in tumor characteristics independent of animal species. Additionally, our pixel-level clustering model can serve as a new diagnostic tool for BTC.
Review
Oncology
Yoshimi Arima, Satoko Matsueda, Hideyuki Saya
Summary: The tumor microenvironment (TME) is a complex network of various cell types and extracellular components, and it has a significant impact on cancer development, therapeutic resistance, and metastasis. Cancer-associated fibroblasts (CAFs) are an important component of TME and interact with cancer cells and other cell types, such as immune cells. Immunocompetent mouse cancer models have been instrumental in understanding the interactions between cancer cells and TME and have contributed to the development of new therapeutic strategies.
Article
Medicine, Research & Experimental
Tomofumi Ando, Ikue Tai-Nagara, Yuki Sugiura, Dai Kusumoto, Koji Okabayashi, Yasuaki Kido, Kohji Sato, Hideyuki Saya, Sutip Navankasattusas, Dean Y. Li, Makoto Suematsu, Yuko Kitagawa, Elena Seiradake, Satoru Yamagishi, Yoshiaki Kubota
Summary: Blood vessel abnormalities in cancer can be targeted therapeutically to suppress cancer progression, according to a study. Researchers found that a molecule called fibronectin leucine-rich transmembrane protein 2 (FLRT2) is expressed in abnormal blood vessels of advanced colorectal cancers in humans. Deleting FLRT2 in endothelial cells selectively pruned abnormal blood vessels and suppressed tumor metastasis. Additionally, FLRT2 deletion increased the number of mature vessels, enhancing the antitumor effects of immune checkpoint blockers. The study suggests that targeting tumor-specific interendothelial adhesions could be a safe and effective therapeutic option.
JOURNAL OF CLINICAL INVESTIGATION
(2022)